12 completed, 8 recruiting, 7 unknown, 5 not yet recruiting. 7 Phase 2, 7 Phase 4, 6 Not applicable, 3 Phase 3.
Follow GLP-1 Receptor Agonist: new trials by email Literature Review of GLP-1 Receptor Agonist trials Research Report on GLP-1 Receptor Agonist
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer GLP-1 Receptor Agonist, Levonorgestrel IUD (Lng-IUD), Oral Progestins - Endometrial Cancer, Endometrial Cancer Stage I | Phase 4 | Not yet recruiting | Hospital Universitari de Bellvitge | 80 | 2027-01-01 | 2026-06-10 |
| GLP-1 RA on Liver OMICS in MASLD GLP-1 receptor agonist - NAFLD, Diabetes | Withdrawn | Medical College of Wisconsin | 2026-07-01 | 2026-07-13 | ||
| Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOS GLP-1 receptor agonist, Metformin - Polycystic Ovary Syndrome (PCOS), Obesity | Not applicable | Not yet recruiting | Peking University Third Hospital | 406 | 2026-07-01 | 2026-07-07 |
| Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes Fecal microbiota transplantation (FMT), Semaglutide (1 Mg Dose), Calorie-restricted diet - Obesity Type 2 Diabetes Mellitus | Not applicable | Not yet recruiting | Eighth Affiliated Hospital, Sun Yat-sen University | 20 | 2026-04-30 | 2026-05-20 |
| Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer GLP-1 receptor agonist, Total neoadjuvant therapy (TNT) - Rectal Cancer Patients, Obesity &Amp; Overweight | Phase 2 | Not yet recruiting | St. James's Hospital, Ireland | 42 | 2026-04-01 | 2026-01-02 |
| Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect) - Liver Cirrhoses, Portal Hypertension Related to Cirrhosis | Phase 4 | Recruiting | The Cleveland Clinic | 70 | 2025-12-17 | 2026-10-22 |
| Comparison of Body Composition Changes With Weight Loss Interventions GLP-1 receptor agonist, Gastric Bypass Surgery (laparoscopic), Gastric Bypass Surgery (robotic) - Obesity | Active not recruiting | Vanderbilt University Medical Center | 60 | 2025-08-09 | 2026-07-14 | |
| Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy GLP-1 receptor agonist, Lifestyle intervention - Obesity in Children, Bone Strength | Phase 2 | Recruiting | University of Virginia | 120 | 2025-07-31 | 2026-04-17 |
| Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity GLP-1 receptor agonist, Metformin, healthy lifestyle education - Polycystic Ovary Syndrome, Obesity | Not applicable | Not yet recruiting | Peking University Third Hospital | 392 | 2025-03-01 | 2025-01-14 |
| Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis GLP-1 Receptor Agonist, Menopausal Hormone Therapy - Menopause, Type 2 Diabetes | Not applicable | Active not recruiting | Lia Bally | 96 | 2025-02-18 | 2026-10-16 |
| Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS GLP-1 receptor agonist, Oral contraceptive, Metformin - PCOS, Hyperinsulinism | Recruiting | Attikon Hospital | 120 | 2024-02-01 | 2025-11-19 | |
| Impact GLP-1 Agonists Following Bariatric GLP-1 receptor agonist - Morbid Obesity, Metabolic Syndrome | Phase 4 | Recruiting | University of Missouri-Columbia | 150 | 2024-02-01 | 2026-10-21 |
| Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM GLP-1 receptor agonist, responders group and nonresponders group - Type 2 Diabetes Mellitus, Susceptibility, Genetic | Not applicable | Recruiting | The Affiliated Hospital of Xuzhou Medical University | 300 | 2024-01-01 | 2025-09-18 |
| Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD GLP-1 receptor agonist, SGLT2 inhibitor, Tirzepatide - Chronic Kidney Disease stage3, Chronic Kidney Disease stage4 | Recruiting | Cardenal Herrera University | 250 | 2023-09-15 | 2025-12-30 | |
| Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes GLP-1 receptor agonist - Diabetes Mellitus, Type 2 | Completed | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | 130 | 2023-06-10 | 2024-01-30 | |
| Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease GLP-1 receptor agonist, basal insulin - Type 2 Diabetes, Chronic Kidney Diseases | Completed | LMC Diabetes & Endocrinology Ltd. | 348 | 2023-02-15 | 2024-02-01 | |
| PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes SGLT2 inhibitor, GLP-1 receptor agonist - Type2Diabetes, ASCVD | Phase 4 | Recruiting | Brigham and Women's Hospital | 6000 | 2022-09-26 | 2026-04-13 |
| Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health GLP-1 receptor agonist - Diabetes Mellitus, Obesity | Unknown | King's College London | 20 | 2022-09-01 | 2022-09-26 | |
| GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) GLP-1 receptor agonist - Cerebral Small Vessel Disease | Phase 2 | Recruiting | Chinese University of Hong Kong | 110 | 2022-05-25 | 2026-06-05 |
| SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. GLP-1 receptor agonist - Weight Loss, Diabetes Mellitus, Type 2 | Completed | Jose Seijas Amigo | 140 | 2022-02-01 | 2024-02-28 |
Showing 20 of 36. Sign in to see all of them.
Diabetes Mellitus, Type 2 (20) · Obesity (12) · Diabetes Mellitus (4) · Overweight (4) · Infertility, Female (2) · Ischemic Stroke (2) · Metabolic Syndrome (2) · Non-alcoholic Fatty Liver Disease (2) · Obesity, Morbid (2) · Pediatric Obesity (2) · Polycystic Ovary Syndrome (2) · Renal Insufficiency, Chronic (2) · Weight Loss (2) · Cerebral Small Vessel Diseases (1) · Cerebrovascular Disorders (1)
Brigham and Women's Hospital (3) · Christina Kruuse (2) · PegBio Co., Ltd. (2) · Peking University Third Hospital (2) · The Affiliated Hospital of Xuzhou Medical University (2) · Attikon Hospital (1) · Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari (1) · Boehringer Ingelheim (1) · Cardenal Herrera University (1) · Chinese University of Hong Kong (1) · Chung Shan Medical University (1) · Dasman Diabetes Institute (1) · Eighth Affiliated Hospital, Sun Yat-sen University (1) · Hospital Universitari de Bellvitge (1) · Jose Seijas Amigo (1)
United States (11) · China (10) · Denmark (2) · Italy (2) · Spain (2) · Canada (1) · Estonia (1) · Greece (1) · Hong Kong (1) · Kuwait (1) · Switzerland (1) · United Kingdom (1)
Alexander Abitbol, MD (1) · Alexander Turchin, MD, MS (1) · Ali Aminian, MD (1) · Ana Checa-Ros, MD, PhD (1) · Andrew Wheeler, MD (1) · Bin Gao, MD,PhD (1) · Bin Gao, MD，PhD (1) · Bonaventure Yiu Ming Ip, MBChB, PhD (1) · Christina R Kruuse, MD, PhD (1) · Christina R Kruuse, MD,PhD (1) · Ebaa AlOzairi, MD, PhD (1) · Francesco Giorgino, PhD (1) · Guixia Wang, MD,PhD (1) · Hui Liu, MD，PhD (1) · HuiMin Zhou, MD，PhD (1)
PMID 30955357, PMID 32591373, PMID 32923389, PMID 33567185, PMID 35565381, PMID 36294412, PMID 36636739, PMID 37085291, PMID 38888262, PMID 38893212, PMID 38948164, PMID 38967919, PMID 39093546, PMID 39113258, PMID 40140925, PMID 40285503, PMID 40437949, PMID 41129847, PMID 41456635, PMID 41806363, PMID 42014131, PMID 42103575, PMID 42865317
2016 (2), R01DK120612 (1), R01HD118635 (1)